BlueBox Precision Medicine Fund
Download FactsheetPrecision Medicine is the fundamental revolution in drug discovery and patient treatment of the 21st century. Traditional medicine is being transformed into patient specific solutions that treat disease at its underlying cause. This intersection of a genomic and biotechnology revolution is changing lives, now.
Fund Launch Date
28 February 2023
Return Since Launch (30/09/2024)
31.1%
Annualised Return since Launch
18.6%
BlueBox Investment Strategy
Precision Medicine
Precision Medicine is a transformational change in what humanity can do to improve people’s lives. It is a more targeted approach to medicine than the one–size-fits-all methods of the last 100+ years. Precision Medicine is only possible due to a confluence of major advances in genomics, molecular biology, biotechnology, chemistry and computing power. This wave of innovation has accelerated through the last 20 years and we expect decades of growth ahead as scientists knowledge grows.
We expect Precision Medicine to lead to greater predictability and better returns for companies and society at large. We invest in companies that are developing, selling or enabling precision medicine and creating substantial value for their outside shareholders.
"More than 25 years ago, as a teenager, I experienced the first "spark" which ignited my insatiable curiosity in medicine. Combining this with the skills needed to be an investor, in the era of Precision Medicine, is an absolute privilege and a joy."
- Mark Dainty
Q&A with Mark Dainty
Have further questions about the fund, click on the video below to hear Mark Dainty briefly review key topics, such as: An overview of the Fund. How this fund is different? What is Precision Medicine? What is the impact of Precision Medicine? What we look for in an investment? The portfolio manager’s experience in the sector?
BlueBox Precision Medicine Fund
Meet the Portfolio Manager
Mark Dainty, MPharm, FCA
Lead Portfolio Manager BBPM
Mark joined BlueBox in 2022 to launch the BlueBox Precision Medicine Fund. He has been researching and investing in the Healthcare sector since 2006. Prior to BlueBox he was the Lead Portfolio Manager of a pharmaceuticals and biotechnology fund at Norges Bank Investment Management for 6 years. He also spent 3 years at Blackrock as a global healthcare analyst and 6 years at Citi in a leading equity research team covering European pharmaceuticals. He holds a Masters in Pharmacy and became a Chartered Accountant (FCA) with KPMG. This combination is critical for evaluating businesses that create lasting value through innovation in the biopharmaceutical sector.
Mark Dainty, MPharm, FCA
Mark joined BlueBox in 2022 to launch the BlueBox Precision Medicine Fund. He has been researching and investing in the Healthcare sector since 2006. Prior to BlueBox he was the Lead Portfolio Manager of a pharmaceuticals and biotechnology fund at Norges Bank Investment Management for 6 years. He also spent 3 years at Blackrock as a global healthcare analyst and 6 years at Citi in a leading equity research team covering European pharmaceuticals. He holds a Masters in Pharmacy and became a Chartered Accountant (FCA) with KPMG. This combination is critical for evaluating businesses that create lasting value through innovation in the biopharmaceutical sector.
TitleCan't find the information you are looking for?
If you require any additional information about BlueBox Asset Management or BlueBox Funds, please do not hesitate to contact us via the link below.
Contact Us